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Background:Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCT) are rare tumors of lowmalignan-
cy. In the past, these tumors were mainly treated by hysterectomy. More recently, some authors have proposed
conservative surgical management for women wishing to preserve fertility. This article is the ﬁrst to report on
organ-preserving treatment in the case of recurrence or disease persistence.
Cases: We report on three patients with UTROSCT, two of them young, not having completed family planning.
One even gave birth to a healthy child after fertility-preserving treatment of a persistent UTROSCT. To our knowl-
edge, this is the ﬁrst pregnancy reported after surgical treatment of a persistent UTROSCT so far.
Conclusion: A fertility-sparing approach should always be considered in young women with UTROSCT whowish
to preserve their fertility, also in cases of recurrence or disease persistence.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The occurrence of Uterine Tumors Resembling Ovarian Sex Cord Tu-
mors (UTROSCT) was ﬁrst described in 1945 (Morehead and Bowman,
1945). In 1976, a series of 14 cases was added (Clement and Scully,
1976). To date, less than 100 cases of UTROSCT have been published
(Morehead and Bowman, 1945; Clement and Scully, 1976; O'Meara et
al., 2009; Blake et al., 2014; Jeong et al., 2015; De Franciscis et al.,
2016; Berretta et al., 2009; Giordano et al., 2010; Anastasakis et al.,
2008; Hillard et al., 2004; Garuti et al., 2009; De Leval et al., 2010;
Biermann et al., 2008; Gomes et al., 2015; Lantta et al., 1984). According
to theWHO, UTROSCT are classiﬁed in the group of endometrial stromal
and related tumors. The entity is deﬁned as a “neoplasm resembling
ovarian sex cord tumorswithout a component of recognizable endome-
trial stroma” (I.A.R.C. 2014, 4th Ed). The classiﬁcation of UTROSCT found
in literature is sometimes unspeciﬁed and a distinction between the
more aggressive ESTSCLE (endometrial stromal tumors with sex cord-
like elements) and UTROSCT is not made. However, this distinction is
highly important because of the different behavior of these tumors.
UTROSCT are tumors of low malignant potential. They usually be-
have in a benign fashion; however, some may recur. The patients typi-
cally present with a bleeding disorder and/or a uterine mass.
These tumors are usuallywell-demarcatedmyometrial noduleswith
sharp or inﬁltrating borders. Some grow as polyps. They are smoother,
ﬂeshier and yellow to tan compared to leiomyoma. They may present
different histological patterns such as trabecular, glandular, solid, dif-
fuse or mixed. The cytoplasm can be scant or more abundant, often
rich in lipid. The nuclei are small, inconspicuous and mitoses are very
rare.
The immunohistochemical proﬁle is variable. Using a marker
panel (De Leval et al., 2010) is useful with sex cord markers (inhib-
in, calretinin, WT-1), one or more smooth muscle markers (desmin,
h-caldesmon, smooth muscle actin), CD 10 and an epithelial marker
(AE1/AE3 cytokeratin).
Due to potential recurrence and limited experience, in the past,
UTROSCT were mainly treated by hysterectomy. More recently, con-
servative surgical management for women wishing to preserve fer-
tility has been proposed (O'Meara et al., 2009; Blake et al., 2014;
Jeong et al., 2015; De Franciscis et al., 2016; Berretta et al., 2009;
Giordano et al., 2010; Anastasakis et al., 2008; Hillard et al., 2004;
Garuti et al., 2009).
In this article, we report on three patients with UTROSCT, two of
them young, not having completed family planning. One of them even
gave birth to a healthy child after a second extensive fertility-sparing
surgical treatment. To our knowledge, this is the ﬁrst pregnancy report-
ed under these conditions so far (Blake et al., 2014; Jeong et al., 2015;
De Franciscis et al., 2016).
2. Case reports
The ﬁrst patient, a 24-year-old woman, suffered from abnormal
uterine bleeding (hypermenorrhea) and secondary dysmenorrhea.
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Ultrasound examination revealed a persistent submucosal mass resem-
bling a leiomyoma in the fundal anteriorwall of the uterine corpus. Over
a two-year period, the size remained stable. Due to increasing symp-
toms a hysteroscopy (Fig. 1) with resection of the submucosal tumor
was performed. The histological diagnosis was UTROSCT with expres-
sion of calretinin, one of the smooth muscle markers, WT1 and AE1/
AE3 cytokeratin. It did not express inhibin. Three months later a fundal
lesion of 8 mmwas visible in a pelvic MRI. The patient strongly desired
fertility-preserving treatment, so a repeat hysteroscopy with biopsies
was performed, showing no histological evidence of UTROSCT. We
agreed on regular clinical surveillance visitswith imaging by ultrasound
or additionally MRI. Sixmonths later, a pelvicMRI suggested disease re-
currencewith a uterinemass of 15mm. The patient strongly desired an-
other fertility-preserving surgery. The diagnostic hysteroscopy showed
no abnormalities. In the concurrent open abdominal surgery, the intra-
mural tumor was located by palpation and completely resected. Patho-
logical results were consistent with UTROSCT. Themargins were free of
tumor and the peritoneal lavage did not exhibit any tumor cells. The pa-
tient is under clinical as well as radiological surveillance since the last
surgery and has now been disease free for 56 months.
The second patient, a 28-year-old woman, was referred to us after
the operation of a symptomatic, slowly growing, cystic-solid tumor of
10 cm in the uterine anteriorwall (Fig. 2) performed at another hospital.
The tumor had been completely resected macroscopically through a
lower abdominal incision. However, the surgery was complicated by
strong bleeding and unintended opening of the tumor. The histological
diagnosis was UTROSCT. Because of the possibility of recurrence, the
hospital, where the initial surgerywas performed, recommended a sub-
sequent hysterectomy. As the patient did not want to undergo another
surgery, regular clinical surveillance visits with additional imaging by
MRIwere performed. In the surveillance visit twomonths after surgery,
theMRI indicated disease persistencewith a tumormass of 3 × 4× 5 cm
in the anterior uterinewall (Fig. 3). As family planningwas not complet-
ed, the patient did not wish to undergo a hysterectomy. She was re-
ferred to us for a second opinion and requested fertility-preserving
surgery. There was no evidence of a macroscopic spread of the disease
during open abdominal surgery. A round, yellowish mass the size of
3 × 3 cm(Fig. 4)was found on the anteriorwall of the uterus. In contrast
to the ﬁrst case, the palpated texture was identical to the rest of the
myometrium. The whole tumor was macro- and microscopically re-
moved. The immunohistochemistry showed positivity for calretinin,
one of the smooth muscle markers, WT1 and AE1/AE3 cytokeratin. It
was negative for inhibin.
The patient conceived without any problems and gave birth to a
healthy child by cesarean section 19 months after the last surgery.
Due to completed family planning, an abdominal hysterectomywith si-
multaneous removal of the distal part of the fallopian tubes on both
sides was performed directly after the cesarean section. The entire tis-
sue was free of tumor.
We agreed on the same procedure for oncological surveillance visits
as in the ﬁrst case. In one of the following surveillance visits, 20 months
later, sonography revealed a 7 cm-large, polycystic tumor in the small
pelvis. MRI indicated the same ﬁnding as well as strong activity of the
contrast agent. Because of strong suspicion of recurrence, a third lapa-
rotomywasperformed. The lower abdomen showedperitoneal carcino-
matosis. The polycystic tumor originated from the right adnexa,
inﬁltrating a part of the vaginal wall. The tumor, both adnexa, part of
the vaginal wall as well as the affected peritoneum were removed.
Fig. 1. UTROSCT of the ﬁrst patient in hysteroscopy.
Fig. 2. Original tumor of the second patient in MRI.
Fig. 3. Recurrence of UTROSCT in the second patient (MRI).
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Theﬁnal pathological report showed anUTROSCT inﬁltrating the perito-
neum, the right fallopian tube, both ovaries and the vaginal wall. A com-
plete resection was achieved.
Due to a lack of guidelines for adjuvant treatment, chemotherapy
with 3 cycles of bleomycin, etoposid and cisplatin (BEP) according to
the adjuvant treatment of Sertoli-Leydig-cell tumors was considered.
However, the patient declined chemotherapy. Because of the estrogen
and progesterone positivity of this UTROSCT, an endocrine treatment
with the aromatase inhibitor anastrozole was initiated as an alternative.
The patient is still being monitored clinically and by ultrasound
every three months and by MRI every six months. She is currently dis-
ease free 34 months after the last surgery.
The third patient was a 72-year-old woman with a one-time post-
menopausal bleeding. Sonography only showed an atrophied endome-
trial layer. Diagnostic hysteroscopy with curettage was performed and
was unsuspicious. Pathology showed an UTROSCT inﬁltrating the
endometrium. The tumor was positive for calretinin, one of the smooth
muscle markers, AE1/AE3 cytokeratin and also for inhibin. A total hys-
terectomy with adnexectomy was recommended. An MRI of the pelvic
region before surgery showed no uterine tumor or inﬁltration of other
organs. Nomacroscopic tumorwas found during surgery and pathology
also indicated no further signs of a tumor. The patient is still being
monitored clinically and radiologically and is disease free 46 months
after the last surgery.
3. Discussion
A fertility-preserving option for younger women with UTROSCT has
only recently been suggested by some authors (O'Meara et al., 2009;
Blake et al., 2014; Jeong et al., 2015; De Franciscis et al., 2016; Berretta
et al., 2009; Giordano et al., 2010; Anastasakis et al., 2008; Hillard et
al., 2004; Garuti et al., 2009). The goal of this article is to show that
tumor resection alone, instead of hysterectomy, may be an option for
treating UTROSCT. This is viable even in cases of recurrence or disease
persistence. However, a complete resection of thewhole tumorwithout
harming the external layer is vital, as is generally the case in oncological
surgery.
To the best of our knowledge, this article is the ﬁrst to report on
organ-preserving treatment in cases of recurrence or disease persis-
tence. The recurrence of UTROSCT in the ﬁrst case may have been
caused by incomplete resection during the ﬁrst surgery. The persis-
tent/recurring UTROSCT in the second case was most likely caused by
incomplete resection during the ﬁrst operation and the subsequent
spread of tumor cells into the abdominal cavity. Due to the presence
of tumors in both ovaries, a hematologic pathway for metastasis could
also be discussed.
Follow-up surveillance visits in the reported cases were done regu-
larly, clinically and with imaging by ultrasound or additionally by MRI.
The shortest disease-free interval was six months in the ﬁrst case men-
tioned in this report. To the best of our knowledge, there are only two
cases of recurrent UTROSCT described in literature (O'Meara et al.,
2009; Biermann et al., 2008). In these cases, recurrence after three and
four years were documented (O'Meara et al., 2009; Biermann et al.,
2008). Based on these data, regular and frequent long-term follow-up
controlsmay be recommended, according to the standard gynecological
tumor aftercare programs.
Four successful pregnancies following uterus-sparing treatment of
UTROSCT (Blake et al., 2014; Jeong et al., 2015; De Franciscis et al.,
2016) have been described in themedical literature since 1945. The sec-
ond case mentioned in this article would be the ﬁfth. However, our case
is the ﬁrst pregnancy described after surgical treatment of a persistent
and extensive UTROSCT. Nonetheless, due to the possibility of late
local recurrences and the lack of experience with UTROSCT, hysterecto-
my should be performed after completion of family planning.
According to the literature, chemotherapy with bleomycin,
etoposide and cisplatin seems to be an option for adjuvant treatment
(O'Meara et al., 2009; Gomes et al., 2015). A (follow up) treatment
with anastrozole in tumors with estrogen-/progesterone-receptor posi-
tivity should also be considered. Lantta et al. (1984) suggested in 1984
already that UTROSCT should be tested for steroid receptor expression
to evaluate a possible hormone treatment. However, due to a lack of
cases and data, general recommendations on the type or duration of ad-
juvant treatment with chemotherapy cannot be made.
In conclusion, based on the cases described here, as well as on the
published evidence available, a fertility-sparing approach should always
be considered in women with UTROSCT who wish to preserve their
fertility. If a complete resection of the tumor is achieved, recurring and
persistent UTROSCT can also be treated by uterus-preserving surgery.
The resection of the whole tumor as a complete mass is vital to avoid
the spreading of tumor cells into the abdominal cavity and thus to
reduce the risk of recurrence. Further case reports are needed to prove
the safety of organ-preserving treatment in UTROSCT and to establish
a treatment protocol.
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